Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

Researchers conducted a Phase I/II multicenter study to evaluate the safety, pharmacokinetics, and activity of azacitidine in children with relapsed myelodysplastic syndrome and juvenile myelomonocytic leukemia (MDS/JMML) prior to the second hematopoietic stem cell transplantation.
[Pediatric Drugs]

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News